Skip to navigation Skip to content

Clinical Trial: An online program to reduce depression

Share

Details
Type of MS: PPMS|PRMS|RRMS|SPMS
Treatment mode of action: To reduce depression
Number of Subjects: 200
Medication: online program to reduce depression
Location: California|Missouri|Pennsylvania
Institutions: Penn State University, Cedars-Sinai Medical Center, University of Missouri, Kansas City
  Contact Information
See contact information below

Funding:

National Multiple Sclerosis Society

Description

SUMMARY: Investigators at three sites in the United States and two sites in Germany are recruiting 400 people with all forms of MS for a study testing the effectiveness of a computer training program for overcoming MS-related depression. The lead investigator is Stefan Gold, PhD, at Charité University in Berlin, Germany. The study is funded by the National MS Society. Please note: Two visits to a study site are required.
 
DETAILS
Rationale: Depression is a common symptom experienced by people living with multiple sclerosis. At the same time, MS symptoms such as walking difficulties, cognitive problems, and fatigue can make it difficult to attend sessions with a psychotherapist. Dr. Gold’s team recently conducted a small trial using a fully-automated, computer-based program to reduce depression in people with MS. The program can be accessed over the internet and completed from an individual’s home, eliminating the need to travel. The team’s preliminary results suggested that this program, called “Deprexis," may reduce MS depression.
 
Dr. Gold and colleagues are now conducting a large-scale, phase III trial at five MS centers in Germany and the U.S. to test the effectiveness of the Deprexis computer training program in 400 people with MS.
 
Eligibility and Details: Participants should be over the age of 18, with a diagnosis of MS and symptoms of depression. They should be able to travel to a study site for two clinical assessments, and must have internet access at home. Further details are available by contacting the site nearest you.
 
Participants are being randomly assigned to one of three groups: One group will receive access to the web-based Deprexis program for three months; another group will receive the web-based Deprexis program plus scheduled e-mail contacts once each week for three months; and a third control group will be on a waiting list, and will receive Deprexis only after waiting six months.
 
The primary outcome being assessed is a clinical scale that measures depression. Other outcomes include measures of quality of life, cognitive function, and fatigue. Participants are being evaluated at the beginning of the study, and after three months, six months and 12 months. The first two evaluations require a visit to the study site at which they are enrolled, whereas the last two are completed online.

Institutions & Contact Names:
Penn State University
State College, Pennsylvania
Meg Cadden
Phone: (814) 865-5578
Email: psu.deprexis@gmail.com
 
Cedars-Sinai Medical Center
Los Angeles, California
Rachel Burt
Phone: (310) 423-4008
Email: rachel.burt@cshs.org
 
University of Missouri, Kansas City
Kansas City, Missouri
Julia Smith
Phone: (816) 235-5428 (voicemail box 1)
Email: umkcidems@umkc.edu

Share


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.